Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu.

T Schwaab; L D Lewis; B F Cole; Y Deo; M W Fanger; P Wallace; P M Guyre; P A Kaufman; J A Heaney; A R Schned

doi:10.1097/00002371-200101000-00009

Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu.

Identifier:nobleid.org/w1/20260515/9A25AADE

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/9A25AADE.svg?ark=w1%2F20260515%2F9A25AADE)](https://nobleid.org/work/w1/20260515/9A25AADE)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu.

Identifier:nobleid.org/w1/20260515/9A25AADE

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/9A25AADE.svg?ark=w1%2F20260515%2F9A25AADE)](https://nobleid.org/work/w1/20260515/9A25AADE)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work